PRDX2 silencing alleviates reactive hyperplasia of Müller glial cells in diabetic retinopathy by inhibiting the RhoA/ROCK signaling pathway

doi:10.4239/wjd.v17.i3.115433

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 3

This Article

(36)

(35)

(0)

(14)

(665)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Diabetes. Mar 15, 2026; 17(3): 115433
Published online Mar 15, 2026. doi: 10.4239/wjd.v17.i3.115433

Table 3 Multivariable logistic regression for proliferative diabetic retinopathy risk prediction

Parameter	aOR (95%CI)	P value
Model 1	9.822 (4.012-24.049)	< 0.0001
Model 2	9.097 (2.819-29.355)	0.0002

Binary logistic regression analysis including PRDX2 as a categorized binary variable using the cutoff value of 124.3 pg/mL. PRDX2 was assigned a value of 0 in 25 patients with PRDX2 ≤ 124.3 pg/mL and a value of 1 in 80 patients with PRDX2 > 124.3 pg/mL. Model 1: No modification variables. Model 2: Adjusts for age, hypertension, vascular endothelial growth factor A, fasting blood glucose, serum albumin, albumin/globulin, gamma-glutamyl transpeptidase, serum creatinine, and serum urea. aOR: Adjusted odds ratio; 95%CI: 95% confidence interval.

Full Size Table

Citation: Du XL, Ouyang S, Wang YS, Mao YS, Ren BC, Yu WH. PRDX2 silencing alleviates reactive hyperplasia of Müller glial cells in diabetic retinopathy by inhibiting the RhoA/ROCK signaling pathway. World J Diabetes 2026; 17(3): 115433
URL: https://www.wjgnet.com/1948-9358/full/v17/i3/115433.htm
DOI: https://dx.doi.org/10.4239/wjd.v17.i3.115433

Du XL, Ouyang S, Wang YS, Mao YS, Ren BC, Yu WH. PRDX2 silencing alleviates reactive hyperplasia of Müller glial cells in diabetic retinopathy by inhibiting the RhoA/ROCK signaling pathway. World J Diabetes 2026; 17(3): 115433 [DOI: 10.4239/wjd.v17.i3.115433]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.